Marksans Pharma

Mumbai, India Founded: 2001 • Age: 25 yrs Listed
Pharmaceutical drug formulations are manufactured, developed, and marketed.
Request Access
Report Incorrect Data
Page last updated

About Marksans Pharma

Marksans Pharma is a publicly listed company based in Mumbai (India) founded in 2001 by Mark Saldanha. Pharmaceutical drug formulations are manufactured, developed, and marketed. The company has 98 employees. Marksans Pharma has completed 2 acquisitions, including Access HealthCare and Time-Cap Labs. Its chief executive, as recorded, is Mark Saldanha. Its Indian entity Marksans Pharma Limited reported revenue of ₹3,033 Cr. Marksans Pharma offers products and services including Pharmaceutical Formulations and OTC Consumer Products. Its focus areas include Traditional Pharmaceuticals, Generics and OTC Drugs.

Company details

Marksans Pharma was founded in 2001 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical sector, where drug formulation manufacturing, development, and marketing of finished dosage products are conducted. A range of products including blow fill-seal ampoules, liquid and powder stick-packs, tablets, bottles, suppositories, and pessaries is offered to support diverse pharmaceutical needs.

Recognitions & Rankings of Marksans Pharma

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#368
Valuation
₹15,060 Cr
  • Headquarters Mumbai, India
  • Employees 98
  • Founders Mark Saldanha
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Pharmacy
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website marksanspharma.com
  • Social LinkedIn
  • Legal Name Marksans Pharma Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹13,767 Cr

    MARKSANS · NSE

  • Share Price
    ₹308.75

    +1.65% today

  • Revenue
    ₹2,951 Cr

    FY 2025-26 · +12.5% YoY

  • EBITDA
    ₹601 Cr

    Margin 20.4%

  • Net Profit
    ₹416 Cr

    FY 2025-26 · +9.7% YoY

  • P/E (TTM)
    24.6x

    P/B 4.1x

  • ROE
    15.3%

    ROCE 19.0%

  • Debt / Equity
    0.12

    Interest cover 4.8x

  • Latest Funding Round
    $45.78M (USD), Post-IPO

    Jan 2023

  • Investors
    Orbimed
  • Employee Count
    98
  • Investments & Acquisitions
    Access HealthCare

    & 1 more

Products & Services of Marksans Pharma

Marksans Pharma offers a comprehensive portfolio of products and services, including Pharmaceutical Formulations and OTC Consumer Products.

Pharmaceutical Formulations
Healthcare Products

Finished dosage formulations are produced for various therapeutic segments, including cardiovascular and oncology, with a focus on global distribution

OTC Consumer Products
Self-Care Items

Over-the-counter products are offered for pain management and digestive health, catering to consumer needs in multiple markets

Funding Insights of Marksans Pharma

  • Total Rounds 2
  • Last Round Post-IPO — $45.78M
  • Investors Count 1

All 2 funding rounds of Marksans Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2023$45.78MPost-IPO––
Orbimed
Jun 2015Post-IPO––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Marksans Pharma

Marksans Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Orbimed.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Orbimed
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Premium access

Investor details for Marksans Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Marksans Pharma Limited (Marksans Pharma)

Marksans Pharma Limited is the primary company behind Marksans Pharma. The board of Marksans Pharma Limited currently have 8 directors; the longest-serving is Sandra Saldanha, appointed in 2014. 11 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sandra Saldanha
DIN 00021023
Whole-time director25 Sep 201412 yrs 1 moMarksans Pharma Limited
Mark Saldanha
DIN 00020983
Managing Director06 Oct 201511 yrs 1 moMarksans Pharma Limited
Digant Mahesh Parikh
DIN 00212589
Director14 Mar 20188 yrs 7 moMarksans Pharma Limited
Varddhman Vikramaditya Jain
DIN 08338573
Whole-time director24 Jan 20197 yrs 9 moMarksans Pharma Limited
Abhinna Mohanty Sundar
DIN 00007995
Director11 Jul 20197 yrs 4 moMarksans Pharma Limited
Sunny Sharma
DIN 02267273
Director11 Aug 20215 yrs 2 moMarksans Pharma Limited
Shailaja Vardhan
DIN 10172764
Director30 May 20233 yrs 5 moMarksans Pharma Limited
Srinivas Mishra
DIN 10052055
Director01 Apr 20251 yr 7 moMarksans Pharma Limited

People of Marksans Pharma

2 people are tracked at Marksans Pharma (2 in leadership); the tracked headcount is 98.

NameRoleGroup
Mark Saldanha
Founder, CEO & MDLeadership
Abhinna Sundar Mohanty
DirectorLeadership
Premium access

Complete people profiles for Marksans Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Marksans Pharma

Marksans Pharma is a publicly listed company on the NSE with ticker symbol MARKSANS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date21 Jan 2002
  • Listed onNSE: MARKSANS
  • Listed entityMarksans Pharma Limited
  • Exchange sectorHealth technology
  • ISININE750C01026
  • Share price₹316.95 (-0.09% on the day) · 2026-10-14
  • Market capitalisation₹14,368 Cr
  • Price to earnings27.8
  • EPS (diluted, trailing year)₹11.40
  • Dividend yield0.28%
  • Volume (last session)351,795

Financials of Marksans Pharma

Exchange-reported figures of Marksans Pharma Limited, the listed company behind Marksans Pharma (NSE: MARKSANS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,951 Cr
+12.5% YoY
EBITDA
₹601 Cr
+12.8% YoY
Profit After Tax
₹416 Cr
+9.7% YoY
Net Worth
₹3,023 Cr
+22.5% YoY
Total Assets
₹3,402 Cr
+20.8% YoY
Total Debt
₹343 Cr
+6.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,9512,6232,1771,8521,4911,3761,134
Revenue growth+12.5%+20.5%+17.6%+24.2%+8.3%+21.3%-
EBITDA601533459339259340192
EBITDA margin+20.4%+20.3%+21.1%+18.3%+17.4%+24.7%+17.0%
Profit before tax561504424338248302157
Net profit416380314267185236121
Net profit margin+14.1%+14.5%+14.4%+14.4%+12.4%+17.1%+10.6%
EPS (₹)9.228.406.925.884.515.762.95
Balance sheet
Total assets3,4022,8172,3351,8911,336947685
Net worth3,0232,4672,0651,7451,202886636
Total debt34332224412311134.1029.65
Cash & bank99070467471534921293.73
Net working capital2,2691,7851,5001,391914628387
Cash flow
Cash from operations45820723023799.26179233
Cash from investing(249)(49.01)(141)(259)(84.39)(44.85)(59.58)
Cash from financing(70.93)(65.15)(68.73)19879.51(15.29)(114)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue940841856754720620708682
Revenue growth (YoY)+30.5%+35.6%+20.8%+10.6%+12.2%+5.0%--
Other income18.1525.4035.1720.1421.575.6415.3427.85
EBITDA214213195161144100127139
EBITDA margin+22.8%+25.3%+22.8%+21.3%+20.1%+16.1%+17.9%+20.4%
Depreciation32.1124.8624.2924.3326.9223.1022.7420.69
Interest6.837.006.315.945.826.073.442.67
Profit before tax19420720015113376.59116143
Tax49.9847.1650.9736.9434.2018.4025.3738.19
Net profit14415914911499.1258.1990.73105
EPS (₹)3.113.473.272.502.171.292.002.31
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3411,174853655658600433
Revenue growth+14.2%+37.6%+30.2%-0.5%+9.8%+38.3%-
EBITDA32420814091.9011411471.50
EBITDA margin+24.1%+17.7%+16.4%+14.0%+17.3%+19.0%+16.5%
Profit before tax39224317213213412452.74
Net profit29918713410310498.3737.88
Net profit margin+22.3%+16.0%+15.7%+15.7%+15.8%+16.4%+8.7%
EPS (₹)6.644.152.952.272.542.400.93
Balance sheet
Total assets1,6701,4001,2351,122801621523
Net worth1,6521,3831,2231,111785600506
Total debt12.1310.848.137.6914.3114.3710.81
Cash & bank4472693124402241063.35
Net working capital1,002738649699434260178
Cash flow
Cash from operations21131.0234.0551.7355.97107108
Cash from investing(141)17.24(114)(195)(128)8.87(24.15)
Cash from financing(39.23)(29.92)(26.22)21070.86(13.53)(81.87)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue314321362340320320299312
Revenue growth (YoY)-2.1%+0.5%+20.8%+8.9%+3.8%+25.6%--
Other income57.2417.4727.4815.8658.192.016.6422.51
Total expenses261239256264248250248252
EBITDA52.3582.1110675.4572.0770.0551.7659.94
EBITDA margin+16.7%+25.6%+29.3%+22.2%+22.5%+21.9%+17.3%+19.2%
Depreciation9.058.788.768.838.468.198.187.42
Interest0.340.340.350.360.320.300.310.30
Profit before tax10090.4612482.1212163.5749.9174.73
Tax14.6721.4232.4421.2121.6915.5212.3119.26

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue940841856754720620708682
Revenue growth (YoY)+30.5%+35.6%+20.8%+10.6%+12.2%+5.0%--
Other income18.1525.4035.1720.1421.575.6415.3427.85
EBITDA214213195161144100127139
EBITDA margin+22.8%+25.3%+22.8%+21.3%+20.1%+16.1%+17.9%+20.4%
Depreciation32.1124.8624.2924.3326.9223.1022.7420.69
Interest6.837.006.315.945.826.073.442.67
Profit before tax19420720015113376.59116143
Tax49.9847.1650.9736.9434.2018.4025.3738.19
Net profit14415914911499.1258.1990.73105
EPS (₹)3.113.473.272.502.171.292.002.31
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,9512,6232,1771,8521,4911,3761,134
Revenue growth+12.5%+20.5%+17.6%+24.2%+8.3%+21.3%-
Other income82.5366.3350.4259.3141.856.690.33
Total expenses2,3502,0901,7191,5131,2321,037942
Employee cost421350294239220197168
EBITDA601533459339259340192
EBITDA margin+20.4%+20.3%+21.1%+18.3%+17.4%+24.7%+17.0%
Depreciation98.6383.3974.2751.8544.7836.1526.66
Interest24.1311.6611.209.138.457.998.75
Profit before tax561504424338248302157
Tax14012110972.3360.7063.6236.42
Net profit416380314267185236121
Net profit margin+14.1%+14.5%+14.4%+14.4%+12.4%+17.1%+10.6%
EPS (₹)9.228.406.925.884.515.762.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital45.3245.3245.3245.3240.9340.9340.93
Reserves & surplus2,9782,4222,0201,7001,068846595
Shareholders' funds (net worth)3,0232,4672,0651,7451,202886636
Minority interest29.5222.4720.8519.9120.7018.8613.11
Secured loans29.5923.0929.0941.5941.2918.7418.89
Unsecured loans31429921581.3669.4915.3610.76
Total debt34332224412311134.1029.65
Total liabilities3,4022,8172,3351,8911,336947685
Assets
Gross block1,6051,4131,193828726552563
Net block1,044982776486428309303
Capital work in progress58.5827.119.429.872.5711.680.00
Investments0.000.7426.990.540.440.260.00
Inventories972846618485424404242
Sundry debtors645540453417395272243
Cash & bank balances99070467471534921293.73
Loans & advances11611490.8058.2232.2814.1114.66
Total current assets2,7232,2031,8361,6751,201903594
Total current liabilities454419336284287274207
Net working capital2,2691,7851,5001,391914628387
Total assets3,4022,8172,3351,8911,336947685
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash49640338220611293.7333.54
Net cash from operating activities45820723023799.26179233
Net cash from investing activities(249)(49.01)(141)(259)(84.39)(44.85)(59.58)
Net cash from financing activities(70.93)(65.15)(68.73)19879.51(15.29)(114)
Net change in cash13892.5120.8417694.3811860.19
Closing cash99070467471534921293.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.5%+20.5%+17.6%+24.2%+8.3%+21.3%-
EBITDA growth+12.8%+16.2%+35.2%+31.1%-23.8%+76.7%-
PBT growth+11.2%+19.0%+25.4%+36.4%-18.1%+92.3%+50.7%
Net income growth+9.7%+21.1%+17.7%+44.4%-21.8%+95.4%-
Revenue CAGR (3Y)+16.8%+20.7%+16.5%+17.8%+14.2%+14.7%+13.9%
EBITDA CAGR (3Y)+21.0%+27.2%+10.5%+20.9%+25.1%+63.0%+62.6%
Profitability & leverage
Net income margin+14.2%+14.6%+14.5%+14.3%+12.5%+17.3%+10.7%
Return on capital employed+19.0%+20.2%+20.8%+21.8%+22.8%+38.8%+25.0%
Return on net worth+15.3%+16.9%+16.5%+18.0%+17.9%+31.3%+20.5%
Debt / equity0.120.120.100.080.070.040.11
Long-term debt / equity0.100.100.070.040.020.010.01
Interest cover4.812.602.913.183.952.635.28
Efficiency & per share
Fixed asset turnover1.962.012.152.382.332.472.12
Inventory turnover3.253.583.954.073.604.264.24
Debtors turnover4.985.285.014.564.475.345.40
EPS (₹)9.228.406.925.884.515.762.95
Dividend per share (₹)0.900.800.600.500.250.250.10
Book value per share (₹)66.7154.4445.5738.5127.1021.6615.54
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue314321362340320320299312
Revenue growth (YoY)-2.1%+0.5%+20.8%+8.9%+3.8%+25.6%--
Other income57.2417.4727.4815.8658.192.016.6422.51
Total expenses261239256264248250248252
EBITDA52.3582.1110675.4572.0770.0551.7659.94
EBITDA margin+16.7%+25.6%+29.3%+22.2%+22.5%+21.9%+17.3%+19.2%
Depreciation9.058.788.768.838.468.198.187.42
Interest0.340.340.350.360.320.300.310.30
Profit before tax10090.4612482.1212163.5749.9174.73
Tax14.6721.4232.4421.2121.6915.5212.3119.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3411,174853655658600433
Revenue growth+14.2%+37.6%+30.2%-0.5%+9.8%+38.3%-
Other income10465.7962.0760.4842.2531.160.17
Total expenses1,018966713563545486362
Employee cost12210277.1956.0960.4654.6448.51
EBITDA32420814091.9011411471.50
EBITDA margin+24.1%+17.7%+16.4%+14.0%+17.3%+19.0%+16.5%
Depreciation34.2329.4529.1316.7417.6615.1911.64
Interest1.331.170.993.613.805.357.29
Profit before tax39224317213213412452.74
Tax90.8454.9838.1429.1730.5225.9514.83
Net profit29918713410310498.3737.88
Net profit margin+22.3%+16.0%+15.7%+15.7%+15.8%+16.4%+8.7%
EPS (₹)6.644.152.952.272.542.400.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital45.3245.3245.3245.3240.9340.9340.93
Reserves & surplus1,6071,3381,1771,066651559465
Shareholders' funds (net worth)1,6521,3831,2231,111785600506
Secured loans0.000.000.000.000.000.000.05
Unsecured loans12.1310.848.137.6914.3114.3710.76
Total debt12.1310.848.137.6914.3114.3710.81
Total liabilities1,6701,4001,2351,122801621523
Assets
Gross block603555421319301277247
Net block398383272144136129115
Capital work in progress0.000.000.003.910.000.000.00
Investments267266293266237236236
Inventories18920519113110493.6974.60
Sundry debtors623550370305247169162
Cash & bank balances4472693124402241063.35
Loans & advances49.7358.0047.4636.5214.922.894.23
Total current assets1,3091,081921913589371244
Total current liabilities30734327121415611166.08
Net working capital1,002738649699434260178
Total assets1,6701,4001,2351,122801621523
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash60.2741.9314881.1982.423.351.80
Net cash from operating activities21131.0234.0551.7355.97107108
Net cash from investing activities(141)17.24(114)(195)(128)8.87(24.15)
Net cash from financing activities(39.23)(29.92)(26.22)21070.86(13.53)(81.87)
Net change in cash30.9818.34(106)67.12(1.23)1021.55
Closing cash4472693124402241063.35
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.2%+37.6%+30.2%-0.5%+9.8%+38.3%-
EBITDA growth+55.5%+48.7%+52.3%-19.2%-0.0%+59.1%-
PBT growth+61.0%+41.5%+30.2%-1.8%+8.2%+135.8%-5.8%
Net income growth+59.6%+40.2%+29.9%-1.0%+5.7%+159.7%-
Revenue CAGR (3Y)+27.0%+21.3%+12.5%+14.8%+15.8%+26.7%+26.2%
EBITDA CAGR (3Y)+52.1%+22.3%+7.2%+8.7%+21.5%+57.5%+42.9%
Profitability & leverage
Net income margin+22.4%+16.0%+15.7%+15.7%+15.8%+16.4%+8.8%
Return on capital employed+25.6%+18.6%+14.7%+14.1%+19.5%+22.0%+10.2%
Return on net worth+19.8%+14.5%+11.5%+10.9%+15.0%+17.3%+7.1%
Debt / equity0.010.010.010.010.020.020.09
Long-term debt / equity0.010.010.010.000.010.010.01
Interest cover0.460.650.894.803.965.4312.18
Efficiency & per share
Fixed asset turnover2.322.412.312.112.282.291.84
Inventory turnover6.805.935.305.586.677.135.98
Debtors turnover2.292.552.532.373.173.622.55
EPS (₹)6.644.152.952.272.542.400.93
Dividend per share (₹)0.900.800.600.500.250.250.10
Book value per share (₹)36.4630.5326.9824.5216.9014.6512.35

Investments & Acquisitions by Marksans Pharma

Marksans Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Access HealthCare and Time-Cap Labs.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Access HealthCare
Skin care pharmaceutical products are manufactured by Access HealthCare.
accesshealthcareme.comDubai, United Arab Emirates2019Apr 2022$3.53M
Time-Cap Labs
Pharma company with expertise in tablet coating and specializing in delayed and sustained release dosages
timecaplabs.comFarmingdale, United States1979Jun 2015$28M
Premium access

Complete acquisition details for Marksans Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Marksans Pharma

6 dated milestones of Marksans Pharma across 22 years, from founding to its latest funding, stage changes and deals.

  1. Founded Marksans Pharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round.
  4. Acquisition Acquires Time-Cap Labs.
  5. Acquisition Acquires Access HealthCare.
  6. Funding Latest funding round, Post-IPO, of $45.8M.

Web traffic of Marksans Pharma

The website of Marksans Pharma (marksanspharma.com) receives about 8K visits a month and ranks #2,963,739 among all websites worldwide, #3,607 in Pharmacy.

  • Monthly visits
    8K

    ▲ 14.5% vs previous month

  • Unique visitors
    3.3K

    per month

  • Global rank
    #2,963,739

    among all websites

  • Category rank
    #3,607

    Health · Pharmacy

Similar websites

Websites whose visitors overlap most with Marksans Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
pharmadost.info
pharmadost.info
100%
–
Intas
intaspharma.com
97%
153.7KView details
PharmaHopers
pharmahopers.com
94%
80K#349,390View details
Zeelab Pharmacy
zeelabpharmacy.com
94%
2M#30,906View details
Mangalam Drugs
mangalamdrugs.com
81%
9.9K#1,747,627View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 28 similar websites and full traffic analytics for Marksans Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 28 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Marksans Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Marksans Pharma

MARKSANS: Q2 CONS NET PROFIT 1.41B RUPEES VS 983M (YOY)
Exchange Update • 6 days ago
MARKSANS: Q2 REVENUE 9.4B RUPEES VS 7.2B (YOY)
Exchange Update • 6 days ago
MARKSANS: Q2 EBITDA 2.14B RUPEES VS 1.4B (YOY); Q2 EBITDA MARGIN 22.8% VS 20.04%
Exchange Update • 6 days ago
MARKSANS: Record Q1 revenue and profit, with Europe and acquisitions fueling robust growth
Quartr • 2 months ago
MARKSANS: Record Q1FY27 profit and margin growth driven by UK & Europe and QliniQ acquisition
Quartr • 3 months ago
MARKSANS: Strong revenue and profit growth, with strategic European acquisitions boosting outlook
Quartr • 3 months ago
Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
Reuters • 5 months ago
MARKSANS: FY 2026 delivered record profitability, robust growth, and strong outlook despite cost headwinds
Quartr • 5 months ago
MARKSANS: Record revenue, margin expansion, and strong cash flow drive robust, debt-free growth
Quartr • 5 months ago
MARKSANS: FY 2026 saw record profitability, margin gains, and strong global expansion, with robust outlook
Quartr • 5 months ago
Premium access

Complete news archive for Marksans Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Marksans Pharma

Marksans Pharma was founded in 2001 and raised its 1st funding round 14 years after it was founded.

Marksans Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Mark Saldanha is the CEO of Marksans Pharma, as recorded in our data. They have also founded this company.

Marksans Pharma has 98 employees.

The primary company behind Marksans Pharma, Marksans Pharma Limited, reported revenue of ₹3,033 Cr for FY 2026, up 13% year on year.

Marksans Pharma was founded in 2001 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical sector, where drug formulation manufacturing, development, and marketing of finished dosage products are conducted. A range of products including blow fill-seal ampoules, liquid and powder stick-packs, tablets, bottles, suppositories, and pessaries is offered to support diverse pharmaceutical needs.

Marksans Pharma offers Pharmaceutical Formulations and OTC Consumer Products.

Yes, Marksans Pharma is publicly traded on NSE under the ticker symbol MARKSANS.

Marksans Pharma has made 2 acquisitions, including Access HealthCare, and Time-Cap Labs.

Marksans Pharma has 1 investor. Key investors include Orbimed.

Marksans Pharma operates through Marksans Pharma Limited.

The legal entities of Marksans Pharma currently have 10 directors, including Sandra Saldanha, Varddhman Vikramaditya Jain, Abhinna Mohanty Sundar and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available